Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen Inc (NQ: OCGN )

0.9698 +0.0612 (+6.74%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen Inc

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
33 34 Next >
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OCGN, HMPT and YMM
NEW YORK, NY / ACCESSWIRE / July 29, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to... 
From The Klein Law Firm
Via AccessWire
Topics Fraud Lawsuit
Exposures Financial Legal Product Safety
CLASS ACTION UPDATE for OCGN, BLCT and OTLY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / July 29, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders... 
From Levi & Korsinsky, LLP
Via AccessWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Is Ocugen Worth a Shot Because of the Worsening Pandemic?
While OCGN stock seems like a reasonable speculation based on the worsening Covid-19 crisis, it’s still a tough gamble. 
Via InvestorPlace
Exposures COVID-19
NASDAQ: OCGN Shareholder Notice: Deadline on August 17, 2021 in Lawsuit Against Ocugen, Inc.
San Diego, CA -- (SBWIRE) -- 07/27/2021 -- A Deadline is coming up on August 17, 2021 in the lawsuit for certain investors in Ocugen, Inc. (NASDAQ: OCGN). 
Via SBWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Why Ocugen Stock Rose, Then Slipped Today
An analyst launched coverage of the stock with an extremely bullish note, however... 
Via The Motley Fool
Exposures COVID-19
Ocugen Likely Can’t Get a Boost From the FDA Until 2023
It would likely take until mid-2023 for the FDA to approve Covaxin. By that time, the shot could be obsolete. Sell OCGN stock. 
Via InvestorPlace
Exposures COVID-19 Product Safety
54 Biggest Movers From Yesterday
Gainers Aehr Test Systems (NASDAQ: AEHR) shares climbed 87.9% to close at $6.39 on Monday after the company won a $10.8 million single purchase order from its lead silicon... 
Via Benzinga
Why Shares of Ocugen Climbed Today
The delta variant is lifting the tide of companies associated with COVID testing and prevention. 
Via The Motley Fool
Topics Death
Exposures Death
Ocugen Stock Is Well Past Its Expiration Date and It Shows
There won’t be a market for COVAXIN in the US as vaccination rates continue moving up. OCGN stock doesn’t even warrant the price of a dollar. 
Via InvestorPlace
Why Ocugen Shares Are Rallying Today
Ocugen, Inc. (NASDAQ: OCGN) shares were advancing strongly Thursday after the biopharma issued a regulatory update. Pennsylvania-based Ocugen said it has initiated a rolling... 
Via Benzinga
OCGN INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Ocugen, Inc. Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Why Ocugen Stock Skyrocketed 339% in the First Half of 2021
The big jump resulted from the company's partnership with Bharat Biotech to commercialize COVID-19 vaccine Covaxin. 
Via The Motley Fool
Exposures COVID-19
Ocugen’s Recent Vaccine Efficacy Results Should Have Traders Cheering
While the Delta variant Covid-19 strain threatens the population, OCGN stock investors can count on Ocugen to advance its vaccine candidate. 
Via InvestorPlace
Exposures COVID-19
Why Shares of Ocugen Are Dropping Today
Investors may be getting concerned about how long it may take for COVID-19 vaccine Covaxin to get approved. 
Via The Motley Fool
Exposures COVID-19
The Outlook for Ocugen Stock Has Deteriorated Further
Phase 3 data on Covaxin wasn't outstanding, and there are indications that demand for additional vaccines in the U.S. and Canada will be low for some time. OCGN remains a good stock to short. 
Via InvestorPlace
Exposures COVID-19
What's Next For Ocugen Stock As It Nears Key Resistance Level?
Ocugen Inc. (NASDAQ: OCGN) shares traded higher Tuesday after the company announced that its coronavirus vaccine co-development partner Bharat Biotech reported... 
Via Benzinga
Exposures COVID-19
42 Stocks Moving In Tuesday's Mid-Day Session
Gainers Orbsat Corp. (NASDAQ: OSAT) shares jumped 74% to $9.47. BSQUARE Corporation (NASDAQ: BSQR) shares jumped 48.2% to $5.90 after dropping around 10% on Friday. Bridgeline... 
Via Benzinga
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
3 Reasons Ocugen Stock Should Maintain Its Upward Trajectory
OCGN stock has been counted out of the vaccine race many times, but there is plenty of room for optimism moving forward. 
Via InvestorPlace
OCGN Stock: The Big Covaxin News That Has Ocugen Rallying Today
OCGN stock is racing higher this morning following better-than-expected results from Ocugen's vaccine partner. Here is what you need to know. 
Via InvestorPlace
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Advaxis (NASDAQ:ADXS) stock rose 46.9% to $0.69 during Tuesday's pre-market session. The market value of their outstanding shares is at $100.9 million. Axcella... 
Via Benzinga
Ocugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%
Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to press ahead with plans to file for approval of their COVID-19... 
Via Benzinga
Exposures COVID-19
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Odonate Therapeutics, Inc. (NASDAQ: ODT) shares rose 38.3% to $4.80 in pre-market trading following 13G from Ikarian Capital showing a 5.2% stake in the company. BSQUARE... 
Via Benzinga
Don’t Play the Ocugen Stock Short Squeeze Before You Read This Warning!
Growing trends involving OCGN stock suggest that the bears may have the upper hand this time. 
Via InvestorPlace
Exposures COVID-19
Ocugen Has Had a Good Run, but the Math Says It’s Over
Ocugen was a penny stock is up 180% for the year. But all good things must come to an end. And it’s time to let go of OCGN stock. 
Via InvestorPlace
Exposures COVID-19
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
3 Tips for Coronavirus Investing Right Now
Whether you're a cautious or aggressive investor, there's something for you in this space. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
One Bright Spot for Ocugen Investors
It may equal some coronavirus vaccine revenue ahead. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Odonate Therapeutics (NASDAQ:ODT)... 
Via Benzinga
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.